Jun 2026 (Q2 FY26) — Aug 6, 2026
Globus Medical Q2 FY26 — Strong Spine Growth and Margin Expansion Drive EPS Beat
Read the full callGlobus Medical (GMED) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Globus Medical earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 790 | +5.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 23.1 | +12.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 152 | −25.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$75.65 −1.38% · −$1.06
Performance +27.0% 1Y
1Y: $59.58 on 17 Oct 2025 → $75.65. High $96.82 (20 Apr 2026), low $59.58 (17 Oct 2025).
- Previous close
- $76.71
- 52-week range
- $60.39 – $96.82
- One year
- +22.85%
Overview
- Symbol
- GMED
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Globus Medical Q1 FY26 — Strong Top-line Growth and Raised EPS Guidance
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Globus Medical Q4 FY25 — Record Performance Driven by U.S. Spine and Enabling Technologies
Read the full callEvery analysed call
Globus Medical earnings calls (GMED)
Financials
What the filings say
Net profit, year on year: −25% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 626 | 657 | 598 | 745 | 769 | 826 | 760 | 790 |
| Operating profit | 48 | 60 | 97 | 76 | 137 | 169 | 150 | 182 |
| Operating margin | 7.7% | 9.2% | 16.2% | 10.2% | 17.9% | 20.5% | 19.8% | 23.1% |
| Other income | 9 | -36 | 7 | 112 | 7 | -0 | 7 | 7 |
| Profit before tax | 57 | 25 | 104 | 188 | 144 | 169 | 157 | 190 |
| Tax rate | 9.1% | −7.5% | 27.2% | −7.8% | 17.4% | 16.9% | 20.9% | 20.1% |
| Net profit | 52 | 27 | 75 | 203 | 119 | 141 | 124 | 152 |
| EPS ($ per share) | 0.38 | — | 0.55 | 1.50 | 0.88 | — | 0.92 | 1.12 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | 893 | 1,048 | 1,045 | 1,194 | 1,240 | 1,137 | 1,153 | 1,388 |
| Total liabilities | 115 | 130 | 173 | 216 | 230 | 1,088 | 1,074 | 730 |
| Fixed assets | 172 | 200 | 217 | 221 | 244 | 587 | 562 | 564 |
| Investments | — | — | 187 | 250 | 296 | 50 | 106 | 31 |
| Total assets | 1,301 | 1,532 | 1,679 | 1,957 | 2,076 | 5,086 | 5,252 | 5,303 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 182 | 172 | 199 | 276 | 178 | 243 | 521 | 753 |
| Cash from investing | -193 | -140 | -117 | -376 | -110 | 303 | -176 | -355 |
| Cash from financing | 33 | 24 | -39 | 54 | -110 | -232 | -28 | -679 |
| Net cash flow | 21 | 56 | 44 | -46 | -43 | 317 | 317 | -258 |
| Capital expenditure | -60 | -71 | -64 | -57 | -74 | -78 | -115 | -165 |
| Free cash flow | 122 | 101 | 135 | 219 | 104 | 165 | 405 | 589 |
GMED revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | — | — | — | — | 100% | 100% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 78% ↓ 1 pt
- Non Us 22% ↑ 1 pt
As GMED cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
31 filings between Nov 7, 2025 and Sep 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$17.54M
14 sales by 7 insiders
64% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 16
- Option exercise — converted options into shares
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| ZARRILLI STEPHEN T | — | $4.28M | Aug 18, 2026 |
| Davidar David D | — | $4.17M | Jun 5, 2026 |
| Huller Kelly | — | $3.44M | Feb 25, 2026 |
| TOBIN JAMES R | — | $2.24M | Sep 15, 2026 |
| Kline Kyle | — | $2.03M | Jan 8, 2026 |
| RHOADS ANN D | — | $818.0K | Nov 10, 2025 |
| Norwalk Leslie V | — | $557.6K | Jan 8, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | TOBIN JAMES R Director | Sale | 30,000 | $2.24M |
| Sep 15, 2026 | TOBIN JAMES R Director | Option exercise | 15,000 | $955.2K |
| Sep 15, 2026 | TOBIN JAMES R Director | Option exercise | 15,000 | $806.3K |
| Aug 18, 2026 | ZARRILLI STEPHEN T Director | Option exercise | 25,000 | $1.33M |
| Aug 18, 2026 | ZARRILLI STEPHEN T Director | Sale | 25,000 | $2.18M |
| Jul 27, 2026 | Davidar David D Director | Gift | 2,500 | $0 |
| Jun 5, 2026 | Davidar David D Director | Sale | 25,000 | $2.02M |
| Jun 5, 2026 | Davidar David D Director | Option exercise | 25,000 | $656.8K |
| Jun 4, 2026 | RHOADS ANN D Director | Option exercise | 25,000 | $656.8K |
| Feb 25, 2026 | Huller Kelly EVP, GC, Corporate Secretary | Option exercise 10b5-1 plan | 20,000 | $871.6K |
| Feb 25, 2026 | Huller Kelly EVP, GC, Corporate Secretary | Sale 10b5-1 plan | 20,000 | $1.89M |
| Feb 12, 2026 | Huller Kelly EVP, GC, Corporate Secretary | Option exercise 10b5-1 plan | 10,000 | $456.4K |
| Feb 12, 2026 | Huller Kelly EVP, GC, Corporate Secretary | Sale 10b5-1 plan | 10,000 | $876.7K |
| Jan 8, 2026 | Norwalk Leslie V Director | Sale 10b5-1 plan | 2,000 | $202.2K |
| Jan 8, 2026 | Kline Kyle Senior Vice President, CFO | Option exercise 10b5-1 plan | 3,594 | $186.4K |
| Jan 8, 2026 | Kline Kyle Senior Vice President, CFO | Sale 10b5-1 plan | 3,594 | $363.4K |
| Dec 12, 2025 | Norwalk Leslie V Director | Sale 10b5-1 plan | 4,000 | $355.4K |
| Dec 8, 2025 | Paul David C Executive Chairman | Option exercise | 34,375 | $877.3K |
| Dec 1, 2025 | Kline Kyle Senior Vice President, CFO | Option exercise 10b5-1 plan | 5,000 | $322.2K |
| Dec 1, 2025 | Kline Kyle Senior Vice President, CFO | Option exercise 10b5-1 plan | 4,896 | $311.8K |
| Dec 1, 2025 | Kline Kyle Senior Vice President, CFO | Sale 10b5-1 plan | 18,542 | $1.67M |
| Dec 1, 2025 | Kline Kyle Senior Vice President, CFO | Option exercise 10b5-1 plan | 3,646 | $193.7K |
| Dec 1, 2025 | Kline Kyle Senior Vice President, CFO | Option exercise 10b5-1 plan | 5,000 | $282.1K |
| Nov 25, 2025 | Huller Kelly SVP, GC, Corporate Secretary | Option exercise 10b5-1 plan | 7,500 | $194.7K |
| Nov 25, 2025 | Huller Kelly SVP, GC, Corporate Secretary | Sale 10b5-1 plan | 7,500 | $675.0K |
| Nov 12, 2025 | Davidar David D Director | Option exercise | 25,000 | $638.0K |
| Nov 12, 2025 | Davidar David D Director | Sale | 25,000 | $2.15M |
| Nov 11, 2025 | ZARRILLI STEPHEN T Director | Option exercise | 25,000 | $1.10M |
| Nov 11, 2025 | ZARRILLI STEPHEN T Director | Sale | 25,000 | $2.11M |
| Nov 10, 2025 | RHOADS ANN D Director | Sale 10b5-1 plan | 2,000 | $170.0K |
| Nov 7, 2025 | RHOADS ANN D Director | Sale 10b5-1 plan | 8,000 | $648.0K |
| Sep 15, 2025 | RHOADS ANN D Director | Sale 10b5-1 plan | 10,000 | $584.6K |
| Feb 28, 2025 | RHOADS ANN D Director | Sale 10b5-1 plan | 7,500 | $590.1K |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | Sale 10b5-1 plan | 12,501 | $1.10M |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | Option exercise 10b5-1 plan | 5,833 | $289.6K |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | Option exercise 10b5-1 plan | 8,334 | $444.0K |
| Jan 10, 2025 | Pfeil Keith W COO, CFO | Sale 10b5-1 plan | 1,666 | $148.6K |
| Jan 2, 2025 | Davidar David D Director | Gift | 6,100 | $0 |
| Dec 2, 2024 | Huller Kelly SVP, GC, Corporate Secretary | Option exercise 10b5-1 plan | 2,500 | $60.5K |
| Dec 2, 2024 | Huller Kelly SVP, GC, Corporate Secretary | Sale 10b5-1 plan | 2,500 | $217.5K |
| Nov 22, 2024 | Lemaitre Dan Director | Option exercise | 1,097 | $71.4K |
| Nov 22, 2024 | Davidar David D Director | Sale 10b5-1 plan | 6,746 | $573.4K |
| Nov 22, 2024 | Lemaitre Dan Director | Sale | 1,097 | $93.3K |
| Nov 22, 2024 | Davidar David D Director | Sale 10b5-1 plan | 6,766 | $575.1K |
| Nov 21, 2024 | Scavilla Daniel T President, CEO | Sale 10b5-1 plan | 130,000 | $11.05M |
| Nov 21, 2024 | Lemaitre Dan Director | Option exercise | 13,278 | $863.7K |
| Nov 21, 2024 | Lemaitre Dan Director | Sale | 13,278 | $1.13M |
| Nov 21, 2024 | Davidar David D Director | Sale 10b5-1 plan | 13,234 | $1.12M |
| Nov 21, 2024 | Davidar David D Director | Sale 10b5-1 plan | 13,254 | $1.13M |
| Nov 21, 2024 | Scavilla Daniel T President, CEO | Option exercise 10b5-1 plan | 50,000 | $2.19M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for GLOBUS MEDICAL INC
Free account. Everything above stays public.
Write why you follow GLOBUS MEDICAL INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading